A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung

NCT02185690 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Lungcancer

Interventions

DRUG: Binimetinib
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

University Health Network, Toronto

Collaborators

[object Object]